Melanocortin Receptor Peptides Evidence Guide
Evidence for Melanocortin Receptor Peptides (as a class of early research tool compounds) is too preliminary to support a research protocol with confidence. These are pharmacological tools for receptor characterization, not therapeutic candidates at this stage. For sexual health applications targeting the melanocortin system, bremelanotide (PT-141) is FDA-approved and is the appropriate clinical reference.
Our Take
Evidence for Melanocortin Receptor Peptides (as a class of early research tool compounds) is too preliminary to support a research protocol with confidence. These are pharmacological tools for receptor characterization, not therapeutic candidates at this stage. For sexual health applications targeting the melanocortin system, bremelanotide (PT-141) is FDA-approved and is the appropriate clinical reference.
- Evidence context
- Melanocortin receptor pharmacology research, receptor subtype selectivity studies
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human therapeutic protocol - tool compounds for receptor research only
Benefits and Evidence
- Female Sexual Desire (Bremelanotide): Level A, includes human evidence - Phase III trials (RECONNECT) demonstrated statistically significant increases in sexual desire and reductions in distress related to low desire in premenopausal women with HSDD. FDA approved bremelanotide (Vyleesi) in 2019.
- MC4R-Based Obesity Research: Level C, includes human evidence - Setmelanotide (MC4R agonist) is FDA-approved for rare genetic obesity syndromes (POMC, PCSK1, LEPR deficiency). Broader MC4R agonist research for common obesity has been limited by cardiovascular side effects.
- Anti-Inflammatory (MC System): Level D, mostly non-human evidence - Getting et al. (2003, Blood) showed the MC3R agonist [D-TRP8]-gamma-MSH reduced inflammatory cell infiltration by 60% and TNF-alpha levels by 45% in murine zymosan peritonitis; Leoni et al. (2008, J Leukoc Biol) demonstrated alpha-MSH analog protection against LPS-induced acute lung injury in mice at 1 mg/kg IP.
Side Effects and Warnings
- Nausea (most common, 40% of patients)
- Flushing
- Injection site reactions
- Headache
- Transient blood pressure increase
- Skin hyperpigmentation with repeated use
- Darkening of gums and face
- Bremelanotide is contraindicated in uncontrolled hypertension
Research Dosage References
- <strong>Subcutaneous (bremelanotide/Vyleesi)</strong> - 1.75 mg - As needed, at least 45 min before anticipated sexual activity - FDA-approved dosing for premenopausal HSDD. Maximum one dose per 24 hours, maximum 8 doses per month. Auto-injector pen.
- <strong>Subcutaneous (setmelanotide)</strong> - 1-3 mg daily - Once daily - FDA-approved for rare genetic obesity (POMC, PCSK1, LEPR deficiency). Dose titrated based on response. Not approved for general obesity.
Mechanism of Action
Melanocortin peptides activate specific MC receptor subtypes: 1. MC3R/MC4R activation (sexual function): Bremelanotide activates MC3R and MC4R in the hypothalamus and limbic system, stimulating dopamine release in the mesolimbic pathway and enhancing sexual desire through central arousal mechanisms. 2. MC4R-mediated appetite regulation: MC4R activation in the paraventricular nucleus reduces food intake. Loss-of-function MC4R mutations are the most common monogenic cause of obesity. 3. MC1R (pigmentation): Activation of MC1R on melanocytes drives eumelanin synthesis (basis of Melanotan I/afamelanotide). 4. MC2R (adrenal): ACTH acting on MC2R stimulates cortisol production (not targeted by current therapeutic peptides). 5. MC5R (exocrine function): Involved in sebaceous gland regulation and pheromone signaling. Least studied receptor subtype.
Legal Status
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. Setmelanotide (Imcivree) is FDA-approved for rare genetic obesity disorders. Other melanocortin peptides remain investigational. Prescription only. Not controlled substances.
Primary Sources
- Bremelanotide for hypoactive sexual desire disorder: RECONNECT randomized clinical trial. Obstetrics & Gynecology, 2019.
- The melanocortin system in sexual function: a comprehensive review. Hormones and Behavior, 2007.
- Melanocortin 4 receptor agonism for obesity: current landscape and future directions. Journal of Clinical Endocrinology & Metabolism, 2019.
Quick Answers
Where is the strongest evidence for Melanocortin Receptor Peptides?
Evidence for Melanocortin Receptor Peptides (as a class of early research tool compounds) is too preliminary to support a research protocol with confidence. These are pharmacological tools for receptor characterization, not therapeutic candidates at this stage. For sexual health applications targeting the melanocortin system, bremelanotide (PT-141) is FDA-approved and is the appropriate clinical reference. Evidence context: Melanocortin receptor pharmacology research, receptor subtype selectivity studies.
What are the main side effects of Melanocortin Receptor Peptides?
Melanocortin Receptor Peptides side effects and warning signals include Nausea (most common, 40% of patients), Flushing, Injection site reactions, Headache, and Transient blood pressure increase.
What evidence level is Melanocortin Receptor Peptides?
Melanocortin Receptor Peptides is rated Level D; the listed research status is Early Research.
Popular Questions
- Melanocortin Receptor Peptides Benefits: Evidence, Verdict, and Limits
- Melanocortin Receptor Peptides Side Effects: Safety Signals and Warnings
- Melanocortin Receptor Peptides Research Dosage: Published Protocol Reference
- Is Melanocortin Receptor Peptides Legit? Evidence Grade and Plain-English Verdict
- Melanocortin Receptor Peptides Legal Status: Approval, Research Use, and Regulatory Notes